Last reviewed · How we verify
S-217622
S-217622 is a small molecule that targets the SGLT2 receptor.
S-217622 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.
At a glance
| Generic name | S-217622 |
|---|---|
| Sponsor | Shionogi |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
S-217622 works by inhibiting the sodium-glucose cotransporter 2 (SGLT2) in the kidneys, reducing glucose reabsorption and increasing glucose excretion in the urine. This leads to a decrease in blood glucose levels. S-217622 is being investigated for its potential to improve glycemic control in patients with type 2 diabetes.
Approved indications
- Type 2 diabetes
Common side effects
- Increased risk of diabetic ketoacidosis
Key clinical trials
- Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE): Shionogi Protease Inhibitor (Ensitrelvir) (PHASE3)
- A Study to Compare S-217622 With Placebo in Non-Hospitalized Participants With COVID-19 (PHASE3)
- Phase 3 Study of S-217622 in Prevention of Symptomatic SARS-CoV-2 Infection (PHASE3)
- A Drug-Drug Interaction Study of S-217622 With Combined Oral Contraceptives in Healthy Adult Female Participants (PHASE1)
- Ensitrelvir for Viral Persistence and Inflammation in People Experiencing Long COVID (PHASE2)
- A Study to Assess S-217622 in Participants With Mild and Moderate Hepatic Impairment and Healthy Control Participants (PHASE1)
- A Study to Assess S-217622 in Participants With Renal Impairment and Healthy Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- S-217622 CI brief — competitive landscape report
- S-217622 updates RSS · CI watch RSS
- Shionogi portfolio CI